Drugs / GFH018
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05051241 | Aug 2019 → Aug 2022 | neoplasm | Zhejiang Genfleet Therapeutics Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04914286 | Oct 2021 → Dec 2023 | — | Genfleet Therapeutics (Shanghai) Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05386888 | Sep 2022 → Dec 2023 | non-small cell lung carcinoma | Genfleet Therapeutics (Shanghai) Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GFH018 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05386888 ↗ |
| Action | Inhibit | “GFH018, a small molecule inhibitor blocking TGF-β signal transduction” PMID 38600507 ↗ Apr 2024 |
| Modality | Small molecule | “GFH018, a small molecule inhibitor of transforming growth factor-β receptor I inhibitor” PMID 38600507 ↗ Apr 2024 |
| Route | Oral | “oral GFH018 tablets” NCT04914286 ↗ |
| Target | TGFBR1 | “small molecule inhibitor of transforming growth factor-β receptor I inhibitor” PMID 38600507 ↗ Apr 2024 |